NCT04831619CompletedPhase 3
Contribution of PET (Positron Emission Tomography) Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN
Contribution of PET Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Endometriosis is an inflammatory condition that is often treated by surgery. MRI and ultrasound are used for the preoperative morphological assessment. Currently, only surgery allows the exhaustive and qualitative diagnosis of lesions. The PET scan, fixing in certain inflammatory pathologies and in certain cases of endometriosis, could refine this assessment by evaluating the location of the lesions.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 26 Mar 2021
- Start date
- 12 Dec 2023
- Primary completion date
- 24 Apr 2025
- Lead sponsor
- Centre Hospitalier Universitaire de la Réunion
- Diseases
- Endometriosis
- NCT number
- NCT04831619
- EU CT number
- 2024-520423-88-00
- EudraCT number
- 2019-004361-40
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 15
- From 12 Dec 2023 to the primary completion date, 24 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who has received an injection with GnRH (gonadotropin-releasing hormone ) analogues for less than 3 months (because it induces the quiescence of the disease which is no longer stimulated by estrogen secretion)
- Contraindication to surgery or anesthesia
Other illness
- Patient with a history of heavy abdominopelvic surgery
- Contraindications to PET Scanner (major claustrophobia, contraindication or hypersensitivity to 18-FDG or one of its excipients, contraindication or hypersensitivity to Ultravist® or one of its excipients, etc.)
Other
- Diabetic patient
- Patient unable to understand the interest of the study
- Patient already included in another therapeutic trial with an experimental molecule.
- Persons referred to in articles L1121-5 to L1121-8 of the PHC (public health code) (corresponding to all protected persons: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, minor, and person making the subject to a legal protection measure: guardianship or curators)
Who the study is looking for
- Patient aged over 18 and under 50
- Patient with symptomatic endometriosis with indication for surgery
- Showing at least one typical endometriosis lesion on MRI, greater than 5mm
- Accepting surgical management
- Having signed an informed consent after information
- Affiliate or beneficiary of a social security scheme
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire De La Reunion Coordinator of this site? Confirm its status | St Denis | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.